{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T07:28:41Z","timestamp":1767857321560,"version":"3.49.0"},"reference-count":52,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,12,9]],"date-time":"2016-12-09T00:00:00Z","timestamp":1481241600000},"content-version":"am","delay-in-days":374,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immunology Letters"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1016\/j.imlet.2015.10.005","type":"journal-article","created":{"date-parts":[[2015,10,25]],"date-time":"2015-10-25T03:49:43Z","timestamp":1445744983000},"page":"279-284","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["CD4+ T cell counts in initiation of antiretroviral therapy in HIV infected asymptomatic individuals; controversies and inconsistencies"],"prefix":"10.1016","volume":"168","author":[{"given":"E.K.","family":"Maina","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.Y.","family":"Bonney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.A.","family":"Bukusi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Sedegah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Lartey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.K.","family":"Ampofo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.imlet.2015.10.005_bib0005","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/01.aids.0000199825.34241.49","article-title":"Adherence-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness","volume":"20","author":"Bangsberg","year":"2006","journal-title":"AIDS"},{"key":"10.1016\/j.imlet.2015.10.005_bib0010","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/j.1468-1293.2005.00290.x","article-title":"Determinants of clinical progression in antiretroviral-na\u00efve HIV infected patients starting highly active antiretroviral therapy. Aquitaine Cohort, France, 1996\u20132002","volume":"6","author":"Bonnet","year":"2005","journal-title":"HIV Med."},{"key":"10.1016\/j.imlet.2015.10.005_bib0015","first-page":"997","article-title":"Timing of HAART initiation and clinical outcomes among HIV-1 seroconverters","volume":"29","author":"CASCADE","year":"2012","journal-title":"Changes"},{"key":"10.1016\/j.imlet.2015.10.005_bib0020","doi-asserted-by":"crossref","first-page":"674","DOI":"10.7326\/0003-4819-118-9-199305010-00003","article-title":"CD4+ lymphocytes are an incomplete surrogate marker for clinical progression in persons with asymptomatic HIV infection taking zidovudine","volume":"118","author":"Choi","year":"1993","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.imlet.2015.10.005_bib0025","unstructured":"EACS, European Aids Clinical Society Guidelines. (2014)."},{"key":"10.1016\/j.imlet.2015.10.005_bib0030","first-page":"8","article-title":"Elite controllers and long-term nonprogressors: models for HIV vaccine development?","volume":"005","author":"Okulicz","year":"2012","journal-title":"J. AIDS Clin. Res."},{"key":"10.1016\/j.imlet.2015.10.005_bib0035","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1097\/00126334-200406010-00007","article-title":"Long-term CD4+ T-cell response to highly active antiretroviral therapy according to Baseline CD4+ T-cell count","volume":"36","author":"Garcia","year":"2004","journal-title":"JAIDS J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.imlet.2015.10.005_bib0040","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1093\/cid\/cis750","article-title":"The effect of a universal antiretroviral therapy recommendation on HIV RNA levels among HIV-infected patients entering care with a CD4 count greater than 500\/\u03bcL in a public health setting","volume":"55","author":"Geng","year":"2012","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.imlet.2015.10.005_bib0045","first-page":"1","article-title":"Utility of total lymphocyte count as a surrogate marker for CD4 counts in HIV-1 infected children in Kenya","volume":"229","author":"Githinji","year":"2011","journal-title":"BMC Infect. Dis."},{"key":"10.1016\/j.imlet.2015.10.005_bib0050","series-title":"Cecil Textbook of Medicine","author":"Goldman","year":"2000"},{"key":"10.1016\/j.imlet.2015.10.005_bib0055","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.trstmh.2011.08.007","article-title":"Predictors of immune recovery and the association with late mortality while on antiretroviral treatment in Cambodia","volume":"105","author":"Van Griensven","year":"2011","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"10.1016\/j.imlet.2015.10.005_bib0060","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1056\/NEJM199202133260703","article-title":"A controlled trial of early versus late treatment with zidovudine in symptomatic human immunodeficiency virus infection","volume":"326","author":"Hamilton","year":"1992","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.imlet.2015.10.005_bib0065","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/infdis\/jir699","article-title":"The setpoint study (ACTG A5217): effect of immediate versus deferred antiretroviral therapy on virologic set point in recently HIV-1-infected individuals","volume":"205","author":"Hogan","year":"2012","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.imlet.2015.10.005_bib0070","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1097\/00002030-199814000-00014","article-title":"CD4 cell count as a surrogate endpoint in HIV clinical trials","volume":"12","author":"Hughes","year":"1998","journal-title":"AIDS"},{"key":"10.1016\/j.imlet.2015.10.005_bib0075","doi-asserted-by":"crossref","first-page":"e30881","DOI":"10.1371\/journal.pone.0030881","article-title":"A plasma biomarker signature of immune activation in HIV patients on antiretroviral therapy","volume":"7","author":"Kamat","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.imlet.2015.10.005_bib0080","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1086\/377606","article-title":"When to begin highly active antiretroviral therapy? Evidence supporting initiation of therapy at CD4+ lymphocyte counts <350 cells\/microL","volume":"37","author":"Kaplan","year":"2003","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.imlet.2015.10.005_bib0085","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJM199508173330709","article-title":"Redundant publication: a reminder","volume":"333","author":"Kassirer","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.imlet.2015.10.005_bib0090","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1086\/431484","article-title":"Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells\/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy","volume":"41","author":"Kaufmann","year":"2005","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.imlet.2015.10.005_bib0095","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2188\/jea.16.101","article-title":"Difference of progression to AIDS according to CD4 cell count, plasma HIV RNA level and the use of antiretroviral therapy among HIV patients infected through blood products in Japan","volume":"16","author":"Kawado","year":"2006","journal-title":"J. Epidemiol."},{"key":"10.1016\/j.imlet.2015.10.005_bib0100","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1056\/NEJMp1300458","article-title":"When to start ART in Africa\u2014an urgent research priority","volume":"368","author":"Kevin","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.imlet.2015.10.005_bib0105","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1056\/NEJMoa0807252","article-title":"Effect of early versus deferred antiretroviral therapy for HIV on survival","volume":"360","author":"Kitahata","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.imlet.2015.10.005_bib0110","first-page":"378","article-title":"Total lymphocyte count (TLC) is a useful tool for the timing of opportunistic infection prophylaxis in India and other resource-constrained countries","volume":"31","author":"Kumarasamy","year":"2002","journal-title":"AIDS"},{"key":"10.1016\/j.imlet.2015.10.005_bib0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1742-6405-4-11","article-title":"Predictors of disease progression in HIV infection: a review","volume":"4","author":"Langford","year":"2007","journal-title":"AIDS Res. Ther."},{"key":"10.1016\/j.imlet.2015.10.005_bib0120","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1097\/QAD.0b013e328321823f","article-title":"Changing mortality risk associated with CD4 cell response to antiretroviral therapy in South Africa","volume":"23","author":"Lawn","year":"2009","journal-title":"AIDS"},{"key":"10.1016\/j.imlet.2015.10.005_bib0125","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/QAD.0b013e32834f32f8","article-title":"Long-term complications in patients with poor immunological recovery despite virological successful HAART in Dutch ATHENA cohort","volume":"26","author":"Van Lelyveld","year":"2012","journal-title":"AIDS"},{"key":"10.1016\/j.imlet.2015.10.005_bib0130","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/01.aids.0000162334.12815.5b","article-title":"The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety of nevirapine or efavirenz- based first-line HAART","volume":"19","author":"Van Leth","year":"2005","journal-title":"AIDS"},{"key":"10.1016\/j.imlet.2015.10.005_bib0135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1742-6405-9-4","article-title":"Clinical, demographic and laboratory parameters at HAART initiation associated with decreased post-HAART survival in a U.S. military prospective HIV cohort","volume":"9","author":"Lifson","year":"2012","journal-title":"AIDS Res. Ther."},{"key":"10.1016\/j.imlet.2015.10.005_bib0140","article-title":"Initiation of antiretroviral therapy in early asymptomatic HIV infection","author":"Lundgren","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.imlet.2015.10.005_bib0145","first-page":"1","article-title":"The relative balance between Th17 and regulatory T cell subsets is critical for progression of HIV infection","volume":"5","author":"Maina","year":"2014","journal-title":"J. AIDS Clin. Res."},{"key":"10.1016\/j.imlet.2015.10.005_bib0150","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1097\/01.qai.0000223028.55080.9d","article-title":"Impact of inversion of the CD4\/CD8 ratio on the natural history of HIV-1 infection","volume":"42","author":"Margolick","year":"2006","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.imlet.2015.10.005_bib0155","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S1473-3099(14)70733-9","article-title":"Early versus delayed initiation of highly active antiretroviral therapy for HIV-positive adults with newly diagnosed pulmonary tuberculosis (TB-HAART): a prospective, international, randomised, placebo-controlled trial","volume":"14","author":"Mfinanga","year":"2014","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.imlet.2015.10.005_bib0160","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1172\/JCI113809","article-title":"Immunological abnormalities in human immunodeficiency virus (HIV)- infected asymptomatic homosexual men. HIV affects the immune system before CD4+ T helper cell depletion occurs","volume":"82","author":"Miedema","year":"1988","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.imlet.2015.10.005_bib0165","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1086\/425424","article-title":"Time to virological failure of 3 classes of antiretrovirals after initiation of highly active antiretroviral therapy: results from the EuroSIDA Study Group","volume":"190","author":"Mocroft","year":"2004","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.imlet.2015.10.005_bib0170","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1177\/135965350701200305","article-title":"Risk of discontinuation of nevirapine due to toxic ities in antiretroviral-na\u00efve and experienced HIV-infected patients with high and low CD4+ T-cell counts","volume":"12","author":"Mocroft","year":"2007","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.imlet.2015.10.005_bib0175","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1086\/510746","article-title":"CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression","volume":"44","author":"Moore","year":"2007","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.imlet.2015.10.005_bib0180","doi-asserted-by":"crossref","first-page":"5372","DOI":"10.1182\/blood-2010-12-323162","article-title":"Regulatory T cells control HIV replication in activated T cells through a cAMP-dependent mechanism","volume":"117","author":"Moreno-Fernandez","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.imlet.2015.10.005_bib0185","unstructured":"NIAID, START trial data support starting antiretroviral treatment for HIV as early as possible. http:\/\/sciencespeaksblog.org\/2015\/05\/27\/start-trial-data-support-starting-antiretroviral-treatment-for-hiv-as-early-as-possible\/ (2015)."},{"key":"10.1016\/j.imlet.2015.10.005_bib0190","doi-asserted-by":"crossref","first-page":"620","DOI":"10.7326\/0003-4819-138-8-200304150-00007","article-title":"Survival benefit of initiating antiretroviral therapy in HIV infected persons in different CD4+ cell strata","volume":"138","author":"Palella","year":"2003","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.imlet.2015.10.005_bib0195","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7448\/IAS.16.1.18518","article-title":"Impact on ART initiation of point-of-care CD4 testing at HIV diagnosis among HIV-positive youth in Khayelitsha, South Africa","volume":"16","author":"Patten","year":"2013","journal-title":"J. Int. AIDS Soc."},{"key":"10.1016\/j.imlet.2015.10.005_bib0200","first-page":"1-34","article-title":"Optimal time for initiation of antiretroviral therapy in asymptomatic, HIV-infected, treatment-naive adults","volume":"3","author":"Siegfried","year":"2010","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.imlet.2015.10.005_bib0205","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1086\/379741","article-title":"Improved outcomes with earlier initiation of highly active antiretroviral therapy among human immunodeficiency virus-infected patients who achieve durable virologic suppression: longer follow-up of an observational cohort study","volume":"188","author":"Sterling","year":"2003","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.imlet.2015.10.005_bib0210","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1086\/367934","article-title":"Initiation of highly active antiretroviral therapy at CD4+ T lymphocyte counts of >350 cells\/mm3: disease progression, treatment durability, and drug toxicity","volume":"36","author":"Sterling","year":"2003","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.imlet.2015.10.005_bib0215","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1097\/00126334-200309011-00005","article-title":"A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients","volume":"34","author":"Stern","year":"2003","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.imlet.2015.10.005_bib0220","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/S0140-6736(09)60612-7","article-title":"Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies","volume":"373","author":"Sterne","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.imlet.2015.10.005_bib0225","series-title":"Cost estimates: AIDS Financing Econ","author":"UNAIDS","year":"2009"},{"key":"10.1016\/j.imlet.2015.10.005_bib0230","unstructured":"USDHHS, Panel on Antiretroviral Guidelines for Adults and Adolescents, Guidelines For the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents, Department of Health and Human Services, 2013; http:\/\/aidsinfo.nih.gov\/ContentFiles\/AdultandAdolescentGL.pdf"},{"key":"10.1016\/j.imlet.2015.10.005_bib0235","first-page":"227","article-title":"Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. February 5, 2001","volume":"2","author":"USDHHS","year":"2015","journal-title":"HIV Clin. Trials"},{"key":"10.1016\/j.imlet.2015.10.005_bib0240","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1097\/QAI.0b013e3181acb630","article-title":"Initiation of HAART at higher CD4 cell counts is associated with a lower frequency of antiretroviral drug resistance mutations at virologic failure","volume":"51","author":"Uy","year":"2009","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.imlet.2015.10.005_bib0245","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1097\/QAD.0000000000000188","article-title":"CD4+ cell count at antiretroviral therapy initiation and economic restoration in rural Uganda","volume":"28","author":"Venkataramani","year":"2014","journal-title":"AIDS"},{"key":"10.1016\/j.imlet.2015.10.005_bib0250","series-title":"Antiretroviral Therapy for HIV Infection in Adults and Adolescents: Recommendations for a Public Health Approach-2006 Revision","article-title":"World Health Organization and Charles Gilks and Marco Vitorio guidelines development group","author":"WHO","year":"2006"},{"key":"10.1016\/j.imlet.2015.10.005_bib0255","series-title":"Rapid Advice Antiretroviral Therapy for HIV Infection in Adults and Adolescents","author":"WHO","year":"2009"},{"key":"10.1016\/j.imlet.2015.10.005_bib0260","series-title":"Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection, Recommendations for a Public Health Approach","author":"WHO","year":"2013"}],"container-title":["Immunology Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165247815300468?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165247815300468?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T07:34:24Z","timestamp":1759044864000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165247815300468"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":52,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["S0165247815300468"],"URL":"https:\/\/doi.org\/10.1016\/j.imlet.2015.10.005","relation":{},"ISSN":["0165-2478"],"issn-type":[{"value":"0165-2478","type":"print"}],"subject":[],"published":{"date-parts":[[2015,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CD4+ T cell counts in initiation of antiretroviral therapy in HIV infected asymptomatic individuals; controversies and inconsistencies","name":"articletitle","label":"Article Title"},{"value":"Immunology Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.imlet.2015.10.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 European Federation of Immunological Societies. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}